Laurus Labs (BOM:540222) Debt-to-EBITDA : 2.48 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Laurus Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹17,170 Mil. Laurus Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹8,604 Mil. Laurus Labs's annualized EBITDA for the quarter that ended in Mar. 2024 was ₹10,401 Mil. Laurus Labs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 2.48.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Laurus Labs's Debt-to-EBITDA or its related term are showing as below:

BOM:540222' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.95 Med: 2.11 Max: 3.91
Current: 3.21

During the past 11 years, the highest Debt-to-EBITDA Ratio of Laurus Labs was 3.91. The lowest was 0.95. And the median was 2.11.

BOM:540222's Debt-to-EBITDA is ranked worse than
67.18% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs BOM:540222: 3.21

Laurus Labs Debt-to-EBITDA Historical Data

The historical data trend for Laurus Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laurus Labs Debt-to-EBITDA Chart

Laurus Labs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-EBITDA

Get a 7-Day Free Trial

1.95

0.95

1.26

3.21

Laurus Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															1.75	-	2.81	-	2.48

Competitive Comparison of Laurus Labs's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laurus Labs's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Laurus Labs's Debt-to-EBITDA falls into.

Laurus Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Laurus Labs's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(17170.1	+	8603.9)	/	8038.4
	=	3.21

Laurus Labs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(17170.1	+	8603.9)	/	10400.8
	=	2.48

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Laurus Labs (BOM:540222) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Laurus Labs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Laurus Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Laurus Labs (BOM:540222) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

LAURUSLABS:India

Address

Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034

Website

https://www.lauruslabs.com

Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs (BOM:540222) Headlines

No Headlines